Drug Profile
AZD 2479
Alternative Names: AVP 26452Latest Information Update: 17 Mar 2017
Price :
$50
*
At a glance
- Originator Avanir Pharmaceuticals
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Apolipoprotein A I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Lipid metabolism disorders
Most Recent Events
- 30 Mar 2007 AstraZeneca and Avanir mutually agreed to end their research collaboration and license agreement on AZD 2479
- 30 Mar 2007 Discontinued - Phase-I for Atherosclerosis in USA (PO)
- 30 Mar 2007 Discontinued - Preclinical for Lipid metabolism disorders in USA (PO)